The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EMN 2018 | Immunomodulators for multiple myeloma
Speaking from the 1st European Myeloma Network (EMN) Meeting 2018, held in Turin, Italy, Francesca Gay, MD, of the University of Turin, Turin, Italy, discusses the practical implications of immunomodulators as a form of multiple myeloma (MM) treatment, the effects of these drugs both in the short and long term, and how to manage their most common side effects. Dr Gay also refers to lenalidomide, currently administered to autologous transplant patients, before discussing the difficulties in determining whether treatment should be adjusted based on positive or negative measurable residual disease (MRD) status.
